Issue Date: April 27, 2015
Roche And Curadev Sign IDO1/TDO Pact
Roche is paying Curadev Pharma $25 million up front as part of a research pact to develop small molecules that block IDO1 and TDO, enzymes that help cancer cells hide from the immune system. New Delhi-based Curadev also gets research funding and could reap up to $530 million in milestones if IDO1/TDO inhibitors reach the market. Last October, Roche’s Genentech unit paid NewLink Genetics $150 million for access to its IDO1 inhibitor NLG919.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society